Macomics

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they play in the tumour microenvironment (TME)? LC: […]

UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players of the tumour microenvironment (TME). Most tumours are populated by macrophages […]

Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME).  The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in a major Perspectives review in Nature Reviews Cancer.  […]